Cabergoline vs Pramipexole
FDA Approved vs FDA Approved
avoid Researched · 95% Do not combine pramipexole with cabergoline or other dopamine agonists. Using two dopamine agonists simultaneously is redundant and significantly increases the risk of excessive dopaminergic stimulation, leading to severe nausea, orthostatic hypotension, impulse control disorders, and potential psychiatric effects. Choose one dopamine agonist and use it at an appropriate dose.
Molecular Data
Cabergoline Pramipexole
Weight 451.60 Da 211.33 Da
Half-life ~63-69 hours ~8 hours
Type Ergoline-derived dopamine D2 receptor agonist Non-ergoline dopamine D3 receptor agonist
Key Benefits
Cabergoline
01 Potent suppression of prolactin levels, often normalizing them within days
02 Prevents and reverses prolactin-related gynecomastia from 19-nor compounds
03 Restores sexual function impaired by hyperprolactinemia (libido, erectile function, orgasm)
04 Long half-life (63-69 hours) allows convenient twice-weekly dosing
05 Significantly better tolerated than bromocriptine with fewer gastrointestinal side effects
06 Effective at shrinking prolactin-secreting pituitary tumors
07 Low doses required for bodybuilding prolactin management (0.25-0.5mg twice weekly)
Pramipexole
01 Suppresses prolactin elevation caused by 19-nor anabolic steroids
02 Non-ergoline structure eliminates the risk of cardiac valve fibrosis associated with ergot-derived agents like cabergoline
03 Generally cheaper and more widely available than cabergoline
04 FDA-approved with a well-characterized safety and pharmacokinetic profile
05 Can restore sexual function impaired by prolactin elevation on nandrolone or trenbolone cycles
06 Viable alternative when cabergoline cannot be sourced
Side Effects
Cabergoline
Nausea (especially during initial doses; mitigated by taking with food)
Dizziness or lightheadedness
Headache
Nasal congestion or stuffiness
Fatigue or drowsiness
Orthostatic hypotension (feeling faint when standing up quickly)
Pramipexole
Nausea (very common during initiation; typically resolves with continued use)
Drowsiness and somnolence (often taken at bedtime to manage this)
Dizziness or lightheadedness
Headache
Insomnia (in some users, despite drowsiness being more typical)
Orthostatic hypotension (feeling faint when standing up quickly)
Contraindications
Known hypersensitivity to cabergoline or any ergot alkaloid
History of cardiac valvular disease or clinically significant valvular regurgitation
History of pulmonary, pericardial, or retroperitoneal fibrotic disorders
Uncontrolled hypertension
Concurrent use of dopamine antagonists (antipsychotics, antiemetics acting on D2 receptors)
Severe hepatic impairment (cabergoline is extensively metabolized by the liver)
Known hypersensitivity to pramipexole or any component of the formulation
Concurrent use of other dopamine agonists (cabergoline, bromocriptine)
History of impulse control disorders or pathological gambling
Severe renal impairment (pramipexole is primarily renally excreted; dose adjustment required in moderate impairment)
Concurrent use of dopamine antagonists (antipsychotics, metoclopramide) which oppose pramipexole's mechanism
Research Evidence
Cabergoline Pramipexole
Status FDA Approved FDA Approved
References 5 studies 5 studies
FDA Approved Yes Yes
More comparisons: Trenbolone
This comparison is for educational and research purposes only. Consult a healthcare professional before use.